title: Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
abstract: Current BRAF inhibitors block signaling from monomeric BRAF(V600E), but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.
authors.affiliation: Department of Pharmacology and Molecular Therapeutics, Uniformed Services University for the Health Sciences, Bethesda, MD 20814, USA; Laboratory of Cell and Developmental Signaling, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Kortum
authors.affiliation: Laboratory of Cell and Developmental Signaling, National Cancer Institute at Frederick, Frederick, MD 21702, USA. Electronic address: morrisod@mail.nih.gov.
authors.forename: Deborah K
authors.initials: DK
authors.lastname: Morrison
mesh_terms: D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*
chemical_list: D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf